Talquetamab, a bispecific antibody targeting GPRC5D and CD3, is being evaluated in elderly patients with relapsed/refractory multiple myeloma. Given the high unmet need in this patient population, especially those who are refractory to multiple lines of therapy, the asset presents significant commercial potential. The competitive landscape includes established therapies such as daratumumab and other bispecific antibodies. The combination of talquetamab with daratumumab may enhance efficacy, positioning it favorably against existing treatment regimens. The study's focus on tolerability and efficacy in a frail demographic could lead to a differentiated market entry strategy. Diligence should focus on the regulatory pathway and potential market access challenges, particularly in the context of reimbursement for elderly patients.